DÄ internationalArchive26/2019The use of rapid tranquilization in aggressive behavior

Review article

The use of rapid tranquilization in aggressive behavior

Dtsch Arztebl Int 2019; 116(26): 445-52; DOI: 10.3238/arztebl.2019.0445

Hirsch, S; Steinert, T

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

ZfP Südwürttemberg, Klinik für Psychiatrie und Psychotherapie I der Universität Ulm,
Ravensburg-Weissenau: Dr. med. Sophie Hirsch, B. Sc., Prof. Dr. med. Tilman Steinert
Danksagung
Die Autoren danken Rita Göbel (RG) für die Hilfe bei der Literaturauswahl.
1.Pajonk FG, Schmitt P, Biedler A, et al.: Psychiatric emergencies in prehospital emergency medical systems: a prospective comparison of two urban settings. Gen Hosp Psychiatry 2008; 30: 360–6 CrossRef MEDLINE
2. Ketelsen R, Schulz M, Driessen M: Zwangsmaßnahmen im Vergleich an sechs psychiatrischen Abteilungen. Gesundheitswesen 2011; 73: 105–11 CrossRef MEDLINE
3. Ketelsen R, Zechert C, Driessen M, Schulz M: Characteristics of aggression in the psychiatric hospital and predictors of patients at risk. J Psychiatr Ment Health Nurs 2007; 14: 92–9 CrossRef MEDLINE
4.Scaggs TR, Glass DM, Hutchcraft MG, Weir WB: Prehospital ketamine is a safe and effective treatment for excited delirium in a community hospital based EMS system. Prehosp Disaster Med 2016; 31: 563–9 CrossRef MEDLINE
5.Ho JD, Dawes DM, Nelson RS, et al.: Acidosis and catecholamine evaluation following simulated law enforcement „use of force“ encounters. Acad Emerg Med 2010;17: e60–8 CrossRef MEDLINE
6. Calver L, Drinkwater V, Isbister GK: A prospective study of high dose sedation for rapid tranquilisation of acute behavioural disturbance in an acute mental health unit. BMC Psychiatry 2013; 13: 225 CrossRef MEDLINE PubMed Central
7.Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e. V. (DGPPN): Verhinderung von Zwang: Prävention und Therapie aggressiven Verhaltens bei Erwachsenen. S3-Leitlinie 2018. AWMF-Registernummer 038–022.
8. Berardis D, Fornaro M, Orsolini L, et al.: The role of inhaled loxapine in the reatment of acute agitation in patients with psychiatric disorders: a clinical review. Int J Mol Cell Med 2017; 18 CrossRef MEDLINE PubMed Central
9. Cester-Martinez A, Cortes-Ramas JA, Borraz-Clares D, Pellicer-Gayarre M: New medical approach to out-of-hospital treatment of psychomotor agitation in psychiatric patients: a report of 14 cases. Emergencias 2017; 29: 182–4.
10. Linder LM, Ross CA, Weant KA: Ketamine for the acute management of excited delirium and agitation in the prehospital setting. Pharmacotherapy 2018; 38: 139–51 CrossRef MEDLINE
11. Huf G, Alexander J, Gandhi P, Allen MH: Haloperidol plus promethazine for psychosis-induced aggression. Cochrane Database Syst Rev 2016; 11: CD005146 CrossRef MEDLINE PubMed Central
12.. Ostinelli EG, Jajawi S, Spyridi S, Sayal K, Jayaram MB: Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation). Cochrane Database Syst Rev 2018; 1: CD008074 CrossRef PubMed Central
13. Belgamwar RB, Fenton M: Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses. Cochrane Database Syst Rev 2005; 2: CD003729 CrossRef MEDLINE
14. Ostinelli EG, Brooke-Powney MJ, Li X, Adams CE: Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). Cochrane Database Syst Rev 2017; 7: CD009377 CrossRef MEDLINE PubMed Central
15. Jayakody K, Gibson RC, Kumar A, Gunadasa S: Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. Cochrane Database Syst Rev 2012; 4: CD000525 CrossRef MEDLINE PubMed Central
16.Zaman H, Sampson SJ, Beck ALS, et al.: Benzodiazepines for psychosis-induced aggression or agitation. Cochrane Database Syst Rev 2017; 12: CD003079.
17.Baldacara L, Sanches M, Cordeiro DC, Jackoswski AP: Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Braz J Psychiatry 2011; 33: 30–9 CrossRef
18.Citrome L: Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry 2007; 68: 1876–85 CrossRef
19. Lieberman JA, Stroup TS, McEvoy JP, et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–23 CrossRef MEDLINE
20. Kittipeerachon M, Chaichan W: Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: a pragmatic double-blind randomized trial. Schizophr Res 176: 231–8 CrossRef MEDLINE
21. Kishi T, Matsunaga S, Iwata N: Intramuscular olanzapine for agitated patients: a systematic review and meta-analysis of randomized controlled trials. J Psychiatr Res 2015; 68: 198–209 CrossRef MEDLINE
22. Marder SR, Sorsaburu S, Dunayevich E: Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation. J Clin Psychiatry 2010; 71: 433–41 CrossRef MEDLINE
23.Wilson MP, MacDonald K, Vilke GM, Feifel D: A comparison of the safety of olanzapine and haloperidol in combination with benzodiazepines in emergency department patients with acute agitation. J Emerg Med 2012; 43: 790–7 CrossRef MEDLINE
24. Allen MH, Currier GW: Use of restraints and pharmacotherapy in academic psychiatric emergency services. General Hospital Psychiatry 2004; 26; 42–9 CrossRef MEDLINE
25. Albrecht B, Staiger PK, Hall K, Miller P, Best D, Lubman DI: Benzodiazepine use and aggressive behaviour: a systematic review. Aust N Z J Psychiatry 2014; 48: 1096–14 CrossRef MEDLINE
26. Bieniek SA, Ownby RL, Penalver A, Dominguez RA: A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy 1998; 18: 57–62.
27. O‘Connor L, Rebesco M, Robinson C, et al.: Outcomes of prehospital chemical sedation with ketamine versus haloperidol and benzodiazepine or physical restraint only. Prehosp Emerg Care 2018; 1–9.
28. Currier GW, Chou JCY, Feifel D, et al.: Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry 2004; 65: 386–94 CrossRef MEDLINE
29. Hsu WY, Huang SS, Lee BS, Chiu NY: Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan. J Clin Psychopharmacol 2010; 30: 230–4 CrossRef MEDLINE
30. Walther S, Moggi F, Horn H, et al.: Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine. J Clin Psychopharmacol 2014; 34: 124–8 CrossRef MEDLINE
31. Mullinax S, Shokraneh F, Wilson MP, Adams CE: Oral medication for agitation of psychiatric origin: a scoping review of randomized controlled trials. J Emerg Med 2017; 53: 524–9 CrossRef MEDLINE
32. Pratts M, Citrome L, Grant W, Leso L, Opler LA: A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation. Acta Psychiatr Scand 2014; 130: 61–8 CrossRef MEDLINE
33.Roncero C, Ros-Cucurull E, Palma-Alvarez RF, et al.: Inhaled loxapine for agitation in intoxicated patients: a case series. Clin Neuropharmacol 2017; 40: 281–5 CrossRef MEDLINE PubMed Central
34.Steinert T, Hamann K: External validity of studies on aggressive behavior in patients with schizophrenia: systematic review. CP & EMH; 2012; 8: 74–80 CrossRef MEDLINE PubMed Central
35.Bauer JO, Stenborg D, Lodahl T, Monsted MM: Treatment of agitation in the acute psychiatric setting. An observational study of the effectiveness of intramuscular psychotropic medication. Nord J Psychiatry 2016; 70: 599–605 CrossRef MEDLINE
e1.neuraxpharm Arzneimittel GmbH: Fachinformation für Haloperidol-neuraxpharm Injektionslösung. Stand: Januar 2018. Langenfeld: neuraxpharm Arzneimittel GmbH. Zulassungsnummer 7819.00.02. www.fachinfo.de/suche/fi/021365 (last accessed on 17 March 2019).
e2.Lilly Deutschland: Fachinformation für ZYPREXA 10 mg Pulver. Stand: November 2018. Bad Homburg: Lilly Deutschland GmbH. EU/1/96/022/016. www.fachinfo.de/suche/fi/004447 (last accessed on 17 March 2019).
e3.Pfizer Pharma PFE GmbH: Fachinformation für ZELDOX 20 mg/ml, Pulver und Lösungsmittel zur Herstellung einer Injektionslösung. Stand: November 2016. Berlin: PFIZER PHARMA PFE GmbH. Zulassungsnummer: 53092.00.00. www.fachinfo.de/suche/fi/005810 (last accessed on 16 May 2019).